Top 5 Life Sciences Stocks To Own Right Now

With shares of Corning (NYSE:GLW) trading around $17, is GLW an OUTPERFORM, WAIT AND SEE, or STAY AWAY? Let�� analyze the stock with the relevant sections of our CHEAT SHEET investing framework.

T = Trends for a Stock’s Movement

Corning produces and sells specialty glasses, ceramics, and related materials worldwide. It operates in five segments: Display Technologies, Telecommunications, Environmental Technologies, Specialty Materials, and Life Sciences. Corning has launched Corning Lotus Glass, an environmentally friendly display glass for organic LED and LCD displays that are used in portable devices such as smartphones, tablets, and notebook computers. Smart phones, tablets, notebook computers, and their related materials are seeing explosive growth in developed and developing countries around the world.

Corning on Tuesday announced its results for the fourth quarter and full year of 2013.�Core earnings per share were 29 cents, an increase of 4 percent over last year�� fourth quarter and better than expected. GAAP earnings per share were 30 cents.�Core sales were $2 billion, a 2 percent decline from the comparable period last year.��013 was a very successful year for Corning,��Wendell P. Weeks, chairman, chief executive officer, and president, said in the earnings report. ��e achieved the company�� primary performance goal of restoring earnings growth. This was accomplished by regaining positive momentum in our LCD business and growing the earnings in our other segments. We also delivered on our commitment to enhance shareholder value by increasing the cash dividend and executing more than $1.5 billion in share repurchases. The company�� performance was recognized by a 41% improvement in the year�� share price, a result with which we are delighted.��/p>

Top Information Technology Stocks To Own Right Now: Rochester Medical Corporation(ROCM)

Rochester Medical Corporation engages in the development, manufacture, and marketing of PVC-free and latex-free urinary continence and urine drainage care products for the home and acute care markets. Its home care products include a line of silicone and latex male external catheters for managing male urinary incontinence; intermittent catheters for managing both male and female urinary retention, including Magic 3 line of silicone intermittent catheters; and the FemSoft Insert, a soft, liquid-filled, urethral insert for managing stress urinary incontinence in adult females. The company manufactures male external catheters in six models, including UltraFlex, Pop-On, Wide Band, Natural, Clear Advantage, and Transfix catheters; and intermittent catheters in four versions that include standard, antibacterial, hydrophilic, and antibacterial personal catheters. Its acute care products include a line of standard Foley catheters and Strata brand of Foley catheters; and Strata-NF Catheter, an antibacterial Foley catheter that reduces the incidence of hospital acquired urinary tract infection. The company?s primary customers include distributors, extended care facilities, and individual hospitals and healthcare institutions. It markets its products under the Rochester Medical brand name through a direct sales force in the United States, the United Kingdom, and the Netherlands, as well as through independent distributors in other international markets. The company also supplies its products to various medical product companies for sale under private label brands owned by these companies. Rochester Medical Corporation was founded in 1988 and is headquartered in Stewartville, Minnesota.

Advisors' Opinion:

• [By Ben Levisohn]

  Back in February, my colleague David Englander noted that a potential buyout was one reason to buy shares of Rochester Medical (ROCM). Today, Rochester agreed to be purchased by CR Bard (BCR) for $262 million.

• [By Seth Jayson]

  Calling all cash flows
  When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Rochester Medical (Nasdaq: ROCM  ) , whose recent revenue and earnings are plotted below.

Top 5 Life Sciences Stocks To Own Right Now: Array BioPharma Inc.(ARRY)

Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients afflicted with cancer and inflammatory diseases in North America, Europe, and the Asia Pacific. Its programs under development include ARRY-520, a kinesin spindle protein inhibitor in Phase 2 clinical trial for patients with multiple myeloma; ARRY-614, a p38/Tie-2 dual inhibitor in Phase 1 clinical trial for patients with myelodysplastic syndrome; ARRY-380, a HER2 inhibitor in Phase 1 clinical trial for breast cancer; ARRY-797, a p38 inhibitor in Phase 2 clinical trial for pain; and ARRY-502, a CRTh2 antagonist in Phase 1 clinical trial for allergic inflammation. The company?s partnered drugs in clinical development comprise Selumetinib and AZD8330 MEK inhibitors for cancer in Phase 2 trial; MEK162 and MEK300 MEK inhibitors for cancer in Phase 2 trial; Danoprevir, a Hepatitis C virus protease inhibitor in Phase 2 trial; ARRY-543, a HER2/EGFR inhibitor in Phase 2 trial for solid tumors; and LY2603618, a ChK-1 inhibitor in Phase 2 trial for cancer. Its partnered drugs in clinical development also include AMG 151, a glucokinase activator in Phase 1b trial for Type 2 diabetes; GDC-0068, a AKT inhibitor in Phase 1b trial for cancer; VTX-2337, a toll-like receptor in Phase 1b trial for cancer; VTX-1463, a toll-like receptor in Phase 1b trial for allergy; ARRY-382, a cFMS inhibitor in Phase 1 trial for cancer; and ARRY-575 and GDC-0425, which are ChK-1 inhibitors in Phase 1 trial for cancer. The company has collaborations with Amgen, Inc.; ASLAN Pharmaceuticals Pte Ltd.; AstraZeneca, PLC; Celgene Corporation; Genentech, Inc.; Novartis International Pharmaceutical Ltd.; InterMune, Inc.; Eli Lilly and Company; and VentiRx Pharmaceuticals, Inc for the development and commercialization of the partnered drugs. Array BioPharma Inc. was founded in 1998 and is headquartered in Boulder, Colorado.

Advisors' Opinion:

• [By Keith Speights]

  Breathing easier
  Array BioPharma (NASDAQ: ARRY  ) shares climbed nearly 18% this week. The company announced positive results from a phase 2 study of its experimental asthma drug ARRY-502.

• [By Sean Williams]

  Array BioPharma (NASDAQ: ARRY  ) presented some particularly intriguing findings with its MEK inhibitor, selumetinib, which it has licensed out to AstraZeneca�to treat uveal melanoma (cancer of the eye). Historically this is a very difficult to treat disease, but initial studies of selumetinib more than doubled the time it took for the disease to progress compared to the current standard of treatment, temozolomide. In trials, selumetinib delivered 15.9 weeks without disease progression, an overall response rate of 50%, and major tumor shrinkage exhibited in 15% of patients. For temozolomide, steady disease was only established for a median of seven weeks with no tumor shrinkage present.�

Top 5 Life Sciences Stocks To Own Right Now: Deutsche Bank AG (SBND)

Deutsche Bank AG is a global investment bank. The Company offers a variety of investment, financial and related products and services to private individuals, corporate entities and institutional clients around the world. The Company operates through such divisions as: Private and Business Clients, Asset and Wealth Management, Corporate Banking and Securities, Global Transaction Banking and Non-Core Operations Unit. Deutsche Bank AG is active domestically and in various countries, through the network of numerous branches. In February 2014, the Company and its related bodies corporate ceases to a share holder in the capital of the Company. Advisors' Opinion:

• [By Donald van Deventer]

  Long-duration Treasury Exchange-Traded Funds: (TLH), , (IEF), (DTYL), (DLBL), (ILTB), (TENZ), (ITE), (TLO), (EDV), (VGIT), (VGLT), (TMF), (TYD), (LBND), (UBT), (UST), (TMV), (TYO), (DSTJ), (DSXJ), (SBND), (PST), (DTYS), (DLBS), (TBF), (TTT), (TYNS), (TYBS), (TBX).

Top 5 Life Sciences Stocks To Own Right Now: JetBlue Airways Corporation(JBLU)

JetBlue Airways Corporation provides passenger air transportation services in the United States. As of December 31, 2011, it operated approximately 700 daily flights to 70 destinations in 22 states, Puerto Rico, and Mexico; and 12 countries in the Caribbean and Latin America through a fleet of 120 Airbus A320 aircraft and 49 EMBRAER 190 aircraft. The company, through its subsidiary, LiveTV, LLC, provides in-flight entertainment, voice communication, and data connectivity systems and services for commercial and general aviation aircraft, including live in-seat satellite television, digital satellite radio, wireless aircraft data link service, and cabin surveillance systems. JetBlue Airways Corporation was founded in 1998 and is based in Forest Hills, New York.

Advisors' Opinion:

• [By Ben Levisohn]

  For 2014, IATA is projecting a $9.2 billion net profit for the North American airline industry, almost triple the next geographic region, Asia Pacific at $3.2 billion. This outperformance by the US airline industry has found its way into the stocks which have been very strong over the past three years (e.g. Delta Airlines +309%, Alaska Air +188%, and US Airways/American Airlines +403%). We continue to believe that there is still ample upside to the group and maintain Buy ratings on many of our names. However, we think investors may want to consider less crowded stocks such as United Continental (large cap), JetBlue (JBLU) (small cap) and Republic Airways (RJET) (micro cap) whose shares could outperform the sector as they improve their ROIC ��WACC gaps (in fact,�JetBlue and�Republic Airways both have ROIC < WACC).